ID Q5J0M4_HORSE Unreviewed; 1084 AA.
AC Q5J0M4;
DT 15-FEB-2005, integrated into UniProtKB/TrEMBL.
DT 15-FEB-2005, sequence version 1.
DT 24-JAN-2024, entry version 68.
DE RecName: Full=2'-5' oligoadenylate synthase {ECO:0000256|ARBA:ARBA00012577};
DE EC=2.7.7.84 {ECO:0000256|ARBA:ARBA00012577};
GN Name=OAS3 {ECO:0000313|EMBL:AAT72304.1};
OS Equus caballus (Horse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Laurasiatheria; Perissodactyla; Equidae; Equus.
OX NCBI_TaxID=9796 {ECO:0000313|EMBL:AAT72304.1};
RN [1] {ECO:0000313|EMBL:AAT72304.1}
RP NUCLEOTIDE SEQUENCE.
RX PubMed=16093721; DOI=10.1159/000085670;
RA Perelygin A.A., Lear T.L., Zharkikh A.A., Brinton M.A.;
RT "Structure of equine 2'-5'oligoadenylate synthetase (OAS) gene family and
RT FISH mapping of OAS genes to ECA8p15-->p14 and BTA17q24-->q25.";
RL Cytogenet. Genome Res. 111:51-56(2005).
CC -!- CATALYTIC ACTIVITY:
CC Reaction=3 ATP = 5'-triphosphoadenylyl-(2'->5')-adenylyl-(2'->5')-
CC adenosine + 2 diphosphate; Xref=Rhea:RHEA:34407, ChEBI:CHEBI:30616,
CC ChEBI:CHEBI:33019, ChEBI:CHEBI:67143; EC=2.7.7.84;
CC Evidence={ECO:0000256|ARBA:ARBA00001112};
CC -!- COFACTOR:
CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC Evidence={ECO:0000256|ARBA:ARBA00001946};
CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|ARBA:ARBA00004496}.
CC -!- SIMILARITY: Belongs to the 2-5A synthase family.
CC {ECO:0000256|ARBA:ARBA00009526}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AY569128; AAT72304.1; -; mRNA.
DR RefSeq; NP_001075226.1; NM_001081757.1.
DR AlphaFoldDB; Q5J0M4; -.
DR GeneID; 791225; -.
DR KEGG; ecb:791225; -.
DR CTD; 4940; -.
DR OrthoDB; 4638494at2759; -.
DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR GO; GO:0001730; F:2'-5'-oligoadenylate synthetase activity; IEA:UniProtKB-EC.
DR GO; GO:0051607; P:defense response to virus; IEA:UniProtKB-KW.
DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR CDD; cd05400; NT_2-5OAS_ClassI-CCAase; 3.
DR Gene3D; 1.10.1410.20; 2'-5'-oligoadenylate synthetase 1, domain 2; 3.
DR Gene3D; 3.30.460.10; Beta Polymerase, domain 2; 3.
DR InterPro; IPR018952; 2-5-oligoAdlate_synth_1_dom2/C.
DR InterPro; IPR006117; 2-5OAS_C_CS.
DR InterPro; IPR043518; 2-5OAS_N_CS.
DR InterPro; IPR006116; NT_2-5OAS_ClassI-CCAase.
DR InterPro; IPR043519; NT_sf.
DR InterPro; IPR002934; Polymerase_NTP_transf_dom.
DR PANTHER; PTHR11258:SF4; 2'-5'-OLIGOADENYLATE SYNTHASE 3; 1.
DR PANTHER; PTHR11258; 2-5 OLIGOADENYLATE SYNTHETASE; 1.
DR Pfam; PF01909; NTP_transf_2; 1.
DR Pfam; PF10421; OAS1_C; 3.
DR SUPFAM; SSF81301; Nucleotidyltransferase; 3.
DR SUPFAM; SSF81631; PAP/OAS1 substrate-binding domain; 3.
DR PROSITE; PS00832; 25A_SYNTH_1; 3.
DR PROSITE; PS00833; 25A_SYNTH_2; 2.
DR PROSITE; PS50152; 25A_SYNTH_3; 3.
PE 2: Evidence at transcript level;
KW Antiviral defense {ECO:0000256|ARBA:ARBA00023118};
KW Cytoplasm {ECO:0000256|ARBA:ARBA00022490};
KW Immunity {ECO:0000256|ARBA:ARBA00022859};
KW Innate immunity {ECO:0000256|ARBA:ARBA00022588}.
FT DOMAIN 161..342
FT /note="2'-5'-oligoadenylate synthetase 1"
FT /evidence="ECO:0000259|Pfam:PF10421"
FT DOMAIN 560..744
FT /note="2'-5'-oligoadenylate synthetase 1"
FT /evidence="ECO:0000259|Pfam:PF10421"
FT DOMAIN 780..867
FT /note="Polymerase nucleotidyl transferase"
FT /evidence="ECO:0000259|Pfam:PF01909"
FT DOMAIN 901..1082
FT /note="2'-5'-oligoadenylate synthetase 1"
FT /evidence="ECO:0000259|Pfam:PF10421"
FT REGION 340..408
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ SEQUENCE 1084 AA; 120742 MW; A39D7284372AC2FF CRC64;
MDVYRTPAAE LDGLVARSLQ PPAEFVGAAR RALGNLSAAL RERGGRPGAA AQPWRVLKIG
GSSGRGTALR GGCDSELVIF LDCFKSYEDQ GAHRAEILNE MRALLESSWQ DTVLGLSLEF
PEQNTPGVLQ LRLASTDLEN WMDVSLVPAF DALGQLRTGA KPEPRVYSSL LDSGSRGGEH
AACFAELRRN FVNARPTKLK NLILLVKHWY RQVCPQEASR ELLPPAYALE LLTIFAWERG
CGKDAFSLAQ GLRTVLGLVQ DYRHLCVFWT LNYSFEDPAL RQFLRRQLER PRPVILDPAD
PTWDVGNGAA WRWDLLAKEA ESCCDHPCFL QAARGPVQPW EGPDLPRAGC PGLDHRIQQD
PAQRTPEDSG VLTGVHPSTR KRQPWSPAPG PSSAASIAPR PPQEVSDLSR IPAPELDRFI
QDHLMPSSQF QKQVSKAIDV ILRGLRENCV HKPSRASKGG SFGRGTDLRG GCDAELVIFL
NCFKDYKDQG ARRGQILEEI RAQLESWWQD RVPSLSLKFP EQSAPGALQL QLASAALESR
VDVSLLPAFD AIGQLRAGAK PEPGVYSSLL DSGSRGGEHA ACFAELRRNF VNTRPTKLKN
LILLVKHWYR QVAAQNKGAQ RAGASLPPAY ALELLTIFAW EQGCGEDRFS MAQGLRTVLG
LVQQHRQLCV YWTVNYSFED PALRTHLLGQ LRNPRPLVLD PADPTWNVGQ GSWELLAQEA
AALGTQPCLM SREGTPVQPW DVMPALLCQT PASDLDKFIT EFLQPNRHFL EQVNKAVDTI
CSFLRDNCFR NSPIKVLKGG SSAKGTALRG RSDADLVVFL SCFSQFTEQG NRRAEIISEI
RAQLEACQQE REFEVKFEIS KWENPRVLSF SLTSQTMLDQ SVDFDVLPAF DALGQLVPDS
RPRPQVYVDL IHSYSNAGEY SPCFTELQRN FISSRPTKLK SLIRLVKHWY QQCNKMPKGR
GSLPPQHGLE LLTVYAWEQG GCDCQFSMAE GFRTVLELVR QYRQLCVYWT VNYDNENETV
RDFLKLQLQK PRPIILDPAD PTGNLGPNAR WDLLAKEAVA CMSAPCCMGR DGSPIQPWPV
KAAV
//